TSE:PLI - ProMetic Life Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$0.73 -0.01 (-1.35 %)
(As of 05/21/2018 04:00 PM ET)
Previous CloseC$0.73
Today's RangeC$0.72 - C$0.74
52-Week RangeC$0.63 - C$2.11
Volume208,200 shs
Average Volume1.15 million shs
Market CapitalizationC$1.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.59

About ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences logoProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. It operates through three segments: Small-Molecule Therapeutics, Plasma-Derived Therapeutics, and Bioseparation Technologies. The company offers its technology platform for purification of biologics, drug development, proteomics, and elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, inflammation, autoimmune diseases, oncology, and nephropathies. The Small-Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, chronic kidney diseases/diabetic kidney diseases, and metabolic syndrome and its resulting type 2 diabetes, cystic fibrosis related diabetes and liver steatosis, and Alström syndrome. The Plasma-Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. The Bioseparation Technologies segment develops and commercializes affinity chromatography products related to the bioseparation, pathogen reduction, and protein purification. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

Receive PLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolTSE:PLI
CUSIPN/A
Phone+1-450-7810115

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-73.85%
Return on Equity-48.83%
Return on Assets-26.09%

Miscellaneous

EmployeesN/A
Outstanding Shares710,593,000

ProMetic Life Sciences (TSE:PLI) Frequently Asked Questions

What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLI."

How were ProMetic Life Sciences' earnings last quarter?

ProMetic Life Sciences (TSE:PLI) issued its earnings results on Wednesday, March, 28th. The company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $6.60 million for the quarter. ProMetic Life Sciences had a negative net margin of 73.85% and a negative return on equity of 48.83%. View ProMetic Life Sciences' Earnings History.

When is ProMetic Life Sciences' next earnings date?

ProMetic Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for ProMetic Life Sciences.

What price target have analysts set for PLI?

6 equities research analysts have issued twelve-month price objectives for ProMetic Life Sciences' shares. Their forecasts range from C$0.60 to C$4.00. On average, they anticipate ProMetic Life Sciences' stock price to reach C$1.89 in the next twelve months. View Analyst Ratings for ProMetic Life Sciences.

Who are some of ProMetic Life Sciences' key competitors?

Who are ProMetic Life Sciences' key executives?

ProMetic Life Sciences' management team includes the folowing people:
  • Mr. Pierre Laurin, Pres, CEO & Non-Independent Director (Age 57)
  • Mr. Bruce Pritchard, COO & Interim CFO
  • Mr. Patrick Sartore, Chief Legal Officer & Corp. Sec.
  • Mr. Bruce Wendel, Chief Bus. Devel. Officer & Director (Age 64)
  • Dr. John Moran, Chief Medical Officer (Age 72)

Has ProMetic Life Sciences been receiving favorable news coverage?

Headlines about PLI stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ProMetic Life Sciences earned a coverage optimism score of 0.09 on Accern's scale. They also assigned headlines about the company an impact score of 46.10 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of ProMetic Life Sciences?

Shares of PLI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is ProMetic Life Sciences' stock price today?

One share of PLI stock can currently be purchased for approximately C$0.73.

How big of a company is ProMetic Life Sciences?

ProMetic Life Sciences has a market capitalization of C$1.04 billion.

How can I contact ProMetic Life Sciences?

ProMetic Life Sciences' mailing address is 440 Armand-Frappier Blvd Suite 300, LAVAL, QC H7V 4B4, Canada. The company can be reached via phone at +1-450-7810115.


MarketBeat Community Rating for ProMetic Life Sciences (PLI)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  307 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  441
MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote "Outperform" if you believe PLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ProMetic Life Sciences (TSE:PLI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for ProMetic Life Sciences in the last 12 months. Their average twelve-month price target is C$1.89, suggesting that the stock has a possible upside of 159.13%. The high price target for PLI is C$4.00 and the low price target for PLI is C$0.60. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.672.67
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: C$1.89C$1.89C$3.50C$3.50
Price Target Upside: 159.13% upside174.15% upside150.00% upside150.00% upside

ProMetic Life Sciences (TSE:PLI) Consensus Price Target History

Price Target History for ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences (TSE:PLI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
4/4/2018National Bank FinancialLower Price TargetUnderperformC$1.00 ➝ C$0.75View Rating Details
4/3/2018Canaccord GenuityLower Price TargetC$4.00 ➝ C$2.00View Rating Details
4/2/2018Royal Bank of CanadaLower Price TargetOutperformC$3.50 ➝ C$2.00View Rating Details
4/2/2018CIBCLower Price TargetC$2.15 ➝ C$0.60View Rating Details
4/2/2018TD SecuritiesLower Price TargetC$3.50 ➝ C$2.00View Rating Details
11/20/2017Cantor FitzgeraldReiterated RatingOverweightView Rating Details
7/7/2017ScotiabankLower Price TargetOutperformC$4.75 ➝ C$4.00View Rating Details
10/13/2016Bloom BurtonReiterated RatingHoldView Rating Details
(Data available from 5/21/2016 forward)

Earnings

ProMetic Life Sciences (TSE:PLI) Earnings History and Estimates Chart

Earnings by Quarter for ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences (TSE PLI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018        
3/28/2018Q4 2017C($0.05)C$6.60 millionViewN/AView Earnings Details
11/13/2017Q3 2017C($0.01)C$24.03 millionViewN/AView Earnings Details
8/14/2017Q2 2017C($0.04)C$3.62 millionViewN/AView Earnings Details
5/15/2017Q1 2017C($0.04)C$4.87 millionViewN/AView Earnings Details
3/30/2017Q4 2016C($0.03)C($0.06)C$4.11 millionViewN/AView Earnings Details
11/14/2016Q3 2016C($0.02)C($0.02)C$3.74 millionViewN/AView Earnings Details
8/11/2016Q2 2016C($0.04)C$7.80 millionC$3.30 millionViewN/AView Earnings Details
5/12/2016Q1 2016C($0.03)C($0.03)C$5.80 millionC$5.25 millionViewN/AView Earnings Details
3/30/2016Q4 2015C($0.01)C($0.02)C$12.70 millionC$14.07 millionViewN/AView Earnings Details
11/12/2015Q3 2015C($0.02)C$8.00 millionC$5.66 millionViewN/AView Earnings Details
8/13/2015Q2 2015C($0.02)C$6.30 millionC$2.90 millionViewN/AView Earnings Details
5/13/2015Q1 2015C($0.01)C$1.91 millionViewN/AView Earnings Details
11/13/2014Q3 2014C($0.04)C$2.32 millionViewN/AView Earnings Details
8/14/2014Q2 2014C$0.04C$4.41 millionViewN/AView Earnings Details
5/14/2014Q1 2014C($0.02)C$5.74 millionViewN/AView Earnings Details
3/26/2014Q4 2013C($0.01)C$5.08 millionViewN/AView Earnings Details
8/14/2013Q2 2013C($0.01)C$5.16 millionViewN/AView Earnings Details
11/13/2012Q3 2012C$0.01ViewN/AView Earnings Details
5/14/2012Q1 2012C($0.01)ViewN/AView Earnings Details
3/26/2012Q4 2011C$0.01ViewN/AView Earnings Details
11/14/2011Q3 2011C($0.01)ViewN/AView Earnings Details
6/14/2011Q1 2011C($0.01)ViewN/AView Earnings Details
11/15/2010Q3 2010C($0.01)C($0.01)ViewN/AView Earnings Details
5/11/2010Q1 2010C($0.01)ViewN/AView Earnings Details
5/14/2009Q1 2009C($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ProMetic Life Sciences (TSE:PLI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ProMetic Life Sciences (TSE PLI) Insider Trading and Institutional Ownership History

Insider Trading History for ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences (TSE PLI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/6/2018Dwun-Hou ChenDirectorSell108,566C$0.86C$93,366.76
4/3/2018Martin LeclercInsiderBuy20,000C$0.74C$14,800.00
1/19/2018Steven J BurtonDirectorSell98,075C$1.54C$151,035.50
12/6/2017Bruce WendelDirectorBuy625C$1.00C$625.00
10/18/2017Martin LeclercInsiderBuy10,000C$1.61C$16,100.00
10/6/2017Jonathan BoothInsiderBuy75,000C$1.21C$90,750.00
10/3/2017Bruce WendelDirectorBuy450C$1.28C$576.00
9/13/2017Pierre LaurinDirectorSell82,738C$1.44C$119,142.72
9/12/2017Pierre LaurinDirectorSell82,738C$1.45C$119,970.10
9/11/2017Bruce WendelDirectorBuy7,450C$1.21C$9,014.50
9/7/2017Pierre LaurinDirectorSell41,427C$1.45C$60,069.15
8/25/2017Bruce PritchardInsiderSell84,594C$1.15C$97,283.10
8/24/2017Dwun-Hou ChenDirectorSell32,321C$1.14C$36,845.94
8/24/2017Patrick SartoreInsiderSell64,579C$1.15C$74,265.85
8/22/2017Bruce PritchardInsiderBuy48,400C$1.30C$62,920.00
8/22/2017Simon Geoffrey BestDirectorBuy10,000C$1.29C$12,900.00
8/18/2017Louise MénardDirectorBuy6,400C$1.20C$7,680.00
8/18/2017Patrick SartoreInsiderBuy9,250C$1.21C$11,192.50
8/17/2017Nancy Orr-GaucherDirectorBuy17,200C$1.18C$20,296.00
7/10/2017Louise MénardDirectorSell82,202C$1.60C$131,523.20
6/1/2017Martin LeclercInsiderBuy7,000C$2.04C$14,280.00
5/30/2017Bruce WendelDirectorBuy2,474C$1.52C$3,760.48
5/25/2017Martin LeclercInsiderBuy8,950C$2.03C$18,168.50
5/18/2017Simon Geoffrey BestDirectorBuy10,000C$2.06C$20,600.00
4/19/2017Andrew Trevor BishopDirectorBuy10,000C$2.09C$20,900.00
4/7/2017Bruce PritchardInsiderBuy15,300C$2.18C$33,354.00
2/6/2017Bruce WendelDirectorBuy1,210C$1.66C$2,008.60
10/7/2016Simon Geoffrey BestDirectorBuy2,750C$2.93C$8,057.50
4/6/2016Bruce PritchardInsiderBuy8,800C$3.19C$28,050.88
4/5/2016Bruce WendelDirectorBuy35,200C$2.45C$86,387.84
1/21/2016Raymond Manuel HakimDirectorBuy10,000C$2.77C$27,700.00
1/20/2016Pierre LaurinDirectorBuy2,000C$2.62C$5,240.00
1/19/2016Gregory WeaverInsiderBuy25,000C$2.78C$69,500.00
1/12/2016Louise M�NardDirectorBuy1,867C$2.94C$5,488.98
12/31/2015Kurt Stefan Victor ClulowDirectorBuy273,800C$3.42C$937,737.62
12/29/2015Kurt Stefan Victor ClulowDirectorBuy232,700C$3.22C$749,875.75
12/21/2015Kurt Stefan Victor ClulowDirectorBuy439,500C$3.16C$1,388,160.75
12/4/2015Gregory WeaverInsiderBuy5,000C$2.14C$10,706.50
12/3/2015Gregory WeaverInsiderBuy5,000C$2.24C$11,184.00
12/3/2015Pierre LaurinDirectorSell259,125C$2.99C$774,913.31
11/17/2015Jonathan BoothInsiderBuy25,000C$2.21C$55,225.00
9/30/2015Kurt Stefan Victor ClulowDirectorBuy50,000C$1.43C$71,500.00
9/29/2015Kurt Stefan Victor ClulowDirectorBuy153,400C$1.42C$217,889.36
9/25/2015Raymond Manuel HakimDirectorBuy15,000C$1.69C$25,399.50
9/15/2015Andrew Trevor BishopDirectorBuy10,000C$1.81C$18,100.00
9/8/2015Simon Geoffrey BestDirectorBuy30,000C$1.95C$58,464.00
8/24/2015Nancy Orr-GaucherDirectorBuy2,800C$1.75C$4,900.00
8/21/2015Pierre LaurinDirectorBuy2,400C$1.83C$4,392.00
7/16/2015Simon Geoffrey BestDirectorBuy60,000C$2.43C$145,782.00
7/15/2015Patrick SartoreInsiderSell122,736C$2.30C$282,722.38
7/15/2015Steven J BurtonDirectorSell49,842C$2.30C$114,811.05
7/2/2015Kurt Stefan Victor ClulowDirectorBuy229,900C$2.32C$533,184.08
6/30/2015Kurt Stefan Victor ClulowDirectorBuy770,100C$2.26C$1,742,736.30
6/29/2015Kurt Stefan Victor ClulowDirectorBuy114,750C$2.10C$240,435.68
6/26/2015Kurt Stefan Victor ClulowDirectorBuy885,250C$2.12C$1,879,208.70
6/16/2015Patrick SartoreInsiderBuy2,300C$2.24C$5,152.00
6/12/2015Patrick SartoreInsiderBuy4,000C$2.28C$9,122.00
6/11/2015Louise M�NardDirectorBuy10,000C$2.35C$23,500.00
6/5/2015Raymond Manuel HakimDirectorBuy50,000C$2.45C$122,495.00
6/4/2015Paul MesburisDirectorSell115,593C$2.40C$277,423.20
5/22/2015Nancy Orr-GaucherDirectorSell9,787C$2.47C$24,173.89
4/9/2015Nancy Orr-GaucherDirectorSell9,657C$2.72C$26,267.04
4/7/2015Bruce PritchardInsiderBuy10,200C$2.74C$27,943.92
2/6/2015John Edward MoranDirectorBuy64,500C$1.51C$97,395.00
1/12/2015Patrick SartoreInsiderSell279,656C$1.87C$523,348.24
1/12/2015Pierre LaurinDirectorSell956,264C$1.87C$1,789,552.45
(Data available from 1/1/2013 forward)

Headlines

ProMetic Life Sciences (TSE PLI) News Headlines

Source:
DateHeadline
ProMetic Life Sciences (PLI) Given Average Recommendation of "Buy" by BrokeragesProMetic Life Sciences (PLI) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 18 at 5:39 AM
CANADA STOCKS - TSX rises 0.06 pct, boosted by industrialsCANADA STOCKS - TSX rises 0.06 pct, boosted by industrials
www.reuters.com - May 17 at 8:23 AM
Canadian Exchanges Stock Scanner Concordia International, ProMetic Life Sciences, Cardiome Pharma, and Oncolytics BiotechCanadian Exchanges Stock Scanner Concordia International, ProMetic Life Sciences, Cardiome Pharma, and Oncolytics Biotech
finance.yahoo.com - May 17 at 8:23 AM
Prometic reports its 2018 first quarter highlights and financial resultsPrometic reports its 2018 first quarter highlights and financial results
finance.yahoo.com - May 15 at 5:48 PM
Prometic reports on its 2018 annual and special meeting of shareholders highlightsPrometic reports on its 2018 annual and special meeting of shareholders highlights
finance.yahoo.com - May 10 at 5:56 PM
UPDATE: Prometic Life Sciences Inc. (PLI) Announces Positive Clinical Data from Intravenous Immunoglobulin Pivotal ...UPDATE: Prometic Life Sciences Inc. (PLI) Announces Positive Clinical Data from Intravenous Immunoglobulin Pivotal ...
www.streetinsider.com - May 1 at 5:17 PM
BRIEF-Prometic Reports Positive Clinical Data From Its Intravenous Immunoglobulin Pivotal Phase 3 TrialBRIEF-Prometic Reports Positive Clinical Data From Its Intravenous Immunoglobulin Pivotal Phase 3 Trial
www.reuters.com - May 1 at 5:17 PM
ProMetic Life Sciences (PLI) Receives Consensus Recommendation of "Buy" from AnalystsProMetic Life Sciences (PLI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 23 at 5:29 AM
UPDATE: Prometic Life Sciences Inc. (PLI) Announces New PBI-4050 Clinical Data From Ongoing Alstrom Syndrome Phase 2 TrialUPDATE: Prometic Life Sciences Inc. (PLI) Announces New PBI-4050 Clinical Data From Ongoing Alstrom Syndrome Phase 2 Trial
www.streetinsider.com - April 13 at 8:20 AM
Dwun-Hou Chen Sells 108,566 Shares of ProMetic Life Sciences Inc. (PLI) StockDwun-Hou Chen Sells 108,566 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - April 11 at 10:37 PM
ProMetic Life Sciences Inc. (PLI) to Post FY2018 Earnings of ($0.16) Per Share, Hybridan ForecastsProMetic Life Sciences Inc. (PLI) to Post FY2018 Earnings of ($0.16) Per Share, Hybridan Forecasts
www.americanbankingnews.com - April 11 at 8:55 AM
Aurora And Canopy: Time To Sober Up, 90% DownsideAurora And Canopy: Time To Sober Up, 90% Downside
seekingalpha.com - April 7 at 8:26 AM
Equities Analysts Set Expectations for ProMetic Life Sciences Inc.s FY2018 Earnings (PLI)Equities Analysts Set Expectations for ProMetic Life Sciences Inc.'s FY2018 Earnings (PLI)
www.americanbankingnews.com - April 6 at 7:24 AM
Cantor Fitzgerald Weighs in on ProMetic Life Sciences Inc.s FY2018 Earnings (PLI)Cantor Fitzgerald Weighs in on ProMetic Life Sciences Inc.'s FY2018 Earnings (PLI)
www.americanbankingnews.com - April 5 at 8:40 AM
ProMetic Life Sciences (PLI) PT Lowered to C$0.75 at National Bank FinancialProMetic Life Sciences (PLI) PT Lowered to C$0.75 at National Bank Financial
www.americanbankingnews.com - April 4 at 2:26 PM
ProMetic Life Sciences Inc. (PLI) Insider Buys C$14,800.00 in StockProMetic Life Sciences Inc. (PLI) Insider Buys C$14,800.00 in Stock
www.americanbankingnews.com - April 3 at 4:14 PM
ProMetic Life Sciences (PLI) Price Target Lowered to C$2.00 at Canaccord GenuityProMetic Life Sciences (PLI) Price Target Lowered to C$2.00 at Canaccord Genuity
www.americanbankingnews.com - April 3 at 2:26 PM
CANADA STOCKS-TSX slides as trade war fears weigh on energy and financialsCANADA STOCKS-TSX slides as trade war fears weigh on energy and financials
finance.yahoo.com - April 2 at 5:27 PM
TD Securities Cuts ProMetic Life Sciences (PLI) Price Target to C$2.00TD Securities Cuts ProMetic Life Sciences (PLI) Price Target to C$2.00
www.americanbankingnews.com - April 2 at 2:38 PM
CIBC Lowers ProMetic Life Sciences (PLI) Price Target to C$0.60CIBC Lowers ProMetic Life Sciences (PLI) Price Target to C$0.60
www.americanbankingnews.com - April 2 at 2:38 PM
ProMetic Life Sciences (PLI) Price Target Cut to C$2.00ProMetic Life Sciences (PLI) Price Target Cut to C$2.00
www.americanbankingnews.com - April 2 at 2:38 PM
Prometic: Still A Buy Despite The Delay In Plasminogens BLAPrometic: Still A Buy Despite The Delay In Plasminogen's BLA
seekingalpha.com - April 1 at 5:56 PM
ProMetic Life Sciences Inc. (PLI) Given Average Rating of "Buy" by BrokeragesProMetic Life Sciences Inc. (PLI) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 29 at 3:32 PM
National Bank Financial Lowers ProMetic Life Sciences (PLI) to UnderperformNational Bank Financial Lowers ProMetic Life Sciences (PLI) to Underperform
www.americanbankingnews.com - March 29 at 2:30 PM
Today’s Research Reports on ESSA Pharma Inc., Helius Medical Technologies, Inc., ProMetic Life Sciences Inc. and Resverlogix Corp.Today’s Research Reports on ESSA Pharma Inc., Helius Medical Technologies, Inc., ProMetic Life Sciences Inc. and Resverlogix Corp.
finance.yahoo.com - March 9 at 8:21 AM
Prometic receives Rare Pediatric Disease Designation from US FDA for its Inter-Alpha-Inhibitor-Proteins - PR Newswire (press release)Prometic receives Rare Pediatric Disease Designation from US FDA for its Inter-Alpha-Inhibitor-Proteins - PR Newswire (press release)
www.prnewswire.com - March 5 at 8:18 AM
Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC)Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC)
finance.yahoo.com - February 15 at 9:19 AM
4 Stocks That Have Taken Off This Year! - The Motley Fool Canada4 Stocks That Have Taken Off This Year! - The Motley Fool Canada
www.fool.ca - February 2 at 3:48 PM
ProMetic Life Sciences Inc. (PLI) Receives Average Rating of "Buy" from BrokeragesProMetic Life Sciences Inc. (PLI) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 27 at 3:22 PM
Canadian Stocks Are Falling Despite Rising Commodities - Canadian CommentaryCanadian Stocks Are Falling Despite Rising Commodities - Canadian Commentary
www.nasdaq.com - January 24 at 3:52 PM
Steven J. Burton Sells 98,075 Shares of ProMetic Life Sciences Inc. (PLI) StockSteven J. Burton Sells 98,075 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - January 24 at 12:34 AM
Canadian Stocks Are Little Changed At The Outset - Canadian CommentaryCanadian Stocks Are Little Changed At The Outset - Canadian Commentary
www.nasdaq.com - January 18 at 4:06 PM
ProMetic Life Sciences Inc. (PLI) Given Consensus Recommendation of "Buy" by BrokeragesProMetic Life Sciences Inc. (PLI) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 2 at 3:40 PM
Canadian Stocks Are Slipping As Gold Stocks Retreat - Canadian CommentaryCanadian Stocks Are Slipping As Gold Stocks Retreat - Canadian Commentary
www.nasdaq.com - December 28 at 12:22 PM
BRIEF-Prometics Plasminogen Granted Orphan Drug Designation For Treatment Of IPFBRIEF-Prometic's Plasminogen Granted Orphan Drug Designation For Treatment Of IPF
www.reuters.com - December 18 at 4:34 PM
Prometics Plasminogen (Ryplazim™) granted orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF)Prometic's Plasminogen (Ryplazim™) granted orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF)
finance.yahoo.com - December 18 at 4:34 PM
Canadian Stocks Have Risen Into The Green After Weak Open - Canadian Commentary - NasdaqCanadian Stocks Have Risen Into The Green After Weak Open - Canadian Commentary - Nasdaq
www.nasdaq.com - December 11 at 11:03 AM
Pivotal Data for Prometics Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for ... - PR Newswire (press release)Pivotal Data for Prometic's Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for ... - PR Newswire (press release)
www.prnewswire.com - December 8 at 10:21 AM
ETFs with exposure to ProMetic Life Sciences, Inc. : November 27, 2017ETFs with exposure to ProMetic Life Sciences, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 3:44 PM
ProMetic Life Sciences Inc. (PLI) Receives Overweight Rating from Cantor FitzgeraldProMetic Life Sciences Inc. (PLI) Receives Overweight Rating from Cantor Fitzgerald
www.americanbankingnews.com - November 22 at 6:10 AM
ProMetic Life Sciences Inc. to Post FY2017 Earnings of ($0.19) Per Share, Cantor Fitzgerald Forecasts (PLI)ProMetic Life Sciences Inc. to Post FY2017 Earnings of ($0.19) Per Share, Cantor Fitzgerald Forecasts (PLI)
www.americanbankingnews.com - November 22 at 5:52 AM
FY2017 EPS Estimates for ProMetic Life Sciences Inc. Lifted by Hybridan Llp (PLI)FY2017 EPS Estimates for ProMetic Life Sciences Inc. Lifted by Hybridan Llp (PLI)
www.americanbankingnews.com - November 20 at 1:56 AM
FY2018 EPS Estimates for ProMetic Life Sciences Inc. Increased by National Bank Financial (PLI)FY2018 EPS Estimates for ProMetic Life Sciences Inc. Increased by National Bank Financial (PLI)
www.americanbankingnews.com - November 18 at 8:50 AM
ETFs with exposure to ProMetic Life Sciences, Inc. : November 17, 2017ETFs with exposure to ProMetic Life Sciences, Inc. : November 17, 2017
finance.yahoo.com - November 17 at 2:08 PM
ProMetic Life Sciences And Other High Growth StocksProMetic Life Sciences And Other High Growth Stocks
finance.yahoo.com - November 16 at 9:39 AM
ProMetic Life Sciences, Inc. :PLI-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017ProMetic Life Sciences, Inc. :PLI-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017
finance.yahoo.com - November 16 at 9:39 AM
ProMetic Life Sciences Inc. (PLI) Given New C$2.00 Price Target at National Bank FinancialProMetic Life Sciences Inc. (PLI) Given New C$2.00 Price Target at National Bank Financial
www.americanbankingnews.com - November 15 at 3:00 PM
ProMetic Life Sciences Inc. 2017 Q3 - Results - Earnings Call SlidesProMetic Life Sciences Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 15 at 7:29 AM
Edited Transcript of PLI.TO earnings conference call or presentation 14-Nov-17 4:00pm GMTEdited Transcript of PLI.TO earnings conference call or presentation 14-Nov-17 4:00pm GMT
finance.yahoo.com - November 15 at 7:28 AM
ProMetic Life Sciences Inc. (PLI) Set to Announce Quarterly Earnings on MondayProMetic Life Sciences Inc. (PLI) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - November 10 at 9:56 AM

SEC Filings

ProMetic Life Sciences (TSE:PLI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

ProMetic Life Sciences (TSE PLI) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.